Evidence of objective responses across multiple CAR-T cell and other T cell therapies has established the clinical potential of immune cell therapies beyond haematological malignancies. The field ...
Morning Overview on MSN
Regulators approved a donor-cell therapy to protect adults fighting blood cancer
Adults with blood cancers who need a donor stem cell transplant now have a new defense against one of the procedure’s most ...
A comprehensive review led by Professors Malgorzata Kloc and Xian Chang Li at the Immunobiology and Transplant Science Center ...
New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
A therapy that has revolutionised how we treat blood and skin cancers could become even more effective. Making cancer cells stiffer bolstered the effects of immunotherapy, when the immune system is ...
Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results